Investing.com - Sangamo Therapeutics (NASDAQ: SGMO) reported third quarter EPS of $0.0400, $0.06 better than the analyst estimate of $-0.0200. Revenue for the quarter came in at $49.41M versus the consensus estimate of $20.92M.
Sangamo Therapeutics's stock price closed at $2.71. It is up 207.9500% in the last 3 months and up 796.4600% in the last 12 months.
Sangamo Therapeutics saw positive EPS revisions and negative EPS revisions in the last 90 days. See Sangamo Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Sangamo Therapeutics's Financial Health score is "weak performance".
Check out Sangamo Therapeutics's recent earnings performance, and Sangamo Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar